CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3365080 ◽

2019 ◽

Author(s):

Kenji Tamura ◽

Chiyo K. Imamura ◽

Toshimi Takano ◽

Shigehira Saji ◽

Takeharu Yamanaka ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

A randomized, open-label, phase IV study evaluating palbociclib plus endocrine treatment versus a chemotherapy-based treatment in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (PADMA)

10.1055/s-0038-1651809 ◽

2018 ◽

Author(s):

M Thill ◽

S Seiler ◽

T Decker ◽

C Denkert ◽

K Lübbe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Endocrine Treatment ◽

Open Label ◽

Hormone Receptor Positive ◽

Open Label Phase ◽

Phase Iv

Download Full-text

Abstract P5-14-05: The impact of food on tolerability of abemaciclib in patients with previously treated hormone receptor-positive, HER2-negative, metastatic breast cancer: An open-label, randomized phase 2 study

10.1158/1538-7445.sabcs19-p5-14-05 ◽

2020 ◽

Author(s):

Elgene Lim ◽

Frances Boyle ◽

Meena Okera ◽

Sherene Loi ◽

Sema Sezgin Goksu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Previously Treated ◽

The Impact ◽

Randomized Phase 2

Download Full-text

Abstract OT2-01-08: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), HER2- metastatic breast cancer

10.1158/1538-7445.sabcs16-ot2-01-08 ◽

2017 ◽

Author(s):

V Diéras ◽

E Hamilton ◽

EL Johnston ◽

T Forrester ◽

M Martín

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Phase 2 Study ◽

Previously Treated

Download Full-text

Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs16-ot2-01-07 ◽

2017 ◽

Cited By ~ 1

Author(s):

H Rugo ◽

S Tolaney ◽

M Dickler ◽

P Kabos ◽

C-L Ho ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Phase 2 Study

Download Full-text

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer

International Journal of Cancer ◽

10.1002/ijc.33613 ◽

2021 ◽

Author(s):

Hyehyun Jeong ◽

Jae Ho Jeong ◽

Jeong Eun Kim ◽

Jin‐Hee Ahn ◽

Kyung Hae Jung ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Protective Effects ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Randomized Phase 2

Download Full-text

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)

European Journal of Cancer ◽

10.1016/j.ejca.2018.08.004 ◽

2018 ◽

Vol 103 ◽

pp. 127-136 ◽

Cited By ~ 4

Author(s):

Ji-Yeon Kim ◽

Seock-Ah Im ◽

Kyung Hae Jung ◽

Jungsil Ro ◽

Joohyuk Sohn ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Premenopausal Women ◽

Open Label ◽

Hormone Receptor Positive

Download Full-text

Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial

10.1158/1538-7445.sabcs19-p1-19-08 ◽

2020 ◽

Author(s):

Hans Wildiers ◽

Valentina Boni ◽

Cristina Saura ◽

Mafalda Oliveira ◽

Komal Jhaveri ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Hormone Receptor Positive ◽

Basket Trial

Download Full-text

Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.1042 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 1042-1042 ◽

Cited By ~ 3

Author(s):

Andrew David Seidman ◽

Lee Steven Schwartzberg ◽

Vinay K. Gudena ◽

Peter Rubin ◽

Stew Kroll ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Hormone Receptor ◽

Single Agent ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Study

Download Full-text

An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer

Cancer ◽

10.1002/cncr.26730 ◽

2012 ◽

Vol 118 (17) ◽

pp. 4098-4104 ◽

Cited By ~ 15

Author(s):

Phuong Khanh Morrow ◽

Rashmi K. Murthy ◽

Joe D. Ensor ◽

Gilad S. Gordon ◽

Kim A. Margolin ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

Download Full-text

Pyrotinib or Lapatinib Combined with Capecitabine in Women with HER2-Positive Metastatic Breast Cancer Previously Treated with Taxanes, Anthracyclines, And/Or Trastuzumab: An Open-Label, Randomised, Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3288216 ◽

2018 ◽

Author(s):

Fei Ma ◽

Quchang Ouyang ◽

Binghe Xu ◽

Wei Li ◽

Zefei Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

Previously Treated

Download Full-text